307 related articles for article (PubMed ID: 30894213)
1. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
[TBL] [Abstract][Full Text] [Related]
2. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia.
Rubnitz JE; Inaba H; Ribeiro RC; Pounds S; Rooney B; Bell T; Pui CH; Leung W
J Clin Oncol; 2010 Feb; 28(6):955-9. PubMed ID: 20085940
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
4. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
5. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
[TBL] [Abstract][Full Text] [Related]
7. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia.
Gómez García LM; Escudero A; Mestre C; Fuster Soler JL; Martínez AP; Vagace Valero JM; Vela M; Ruz B; Navarro A; Fernández L; Fernández A; Leivas A; Martínez-López J; Ferreras C; De Paz R; Blanquer M; Galán V; González B; Corral D; Sisinni L; Mirones I; Balas A; Vicario JL; Valle P; Borobia AM; Pérez-Martínez A
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):328-337.e1. PubMed ID: 33610500
[TBL] [Abstract][Full Text] [Related]
9. Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic leukaemia.
Muñoz Builes M; Vela Cuenca M; Fuster Soler JL; Astigarraga I; Pascual Martínez A; Vagace Valero JM; Tong HY; Valentín Quiroga J; Fernández Casanova L; Escudero López A; Sisinni L; Blanquer M; Mirones Aguilar I; González Martínez B; Borobia AM; Pérez-Martínez A
BMJ Open; 2020 Jan; 10(1):e029642. PubMed ID: 31919123
[TBL] [Abstract][Full Text] [Related]
10. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
Vela M; Corral D; Carrasco P; Fernández L; Valentín J; González B; Escudero A; Balas A; de Paz R; Torres J; Leivas A; Martinez-Lopez J; Pérez-Martínez A
Cancer Lett; 2018 May; 422():107-117. PubMed ID: 29477379
[TBL] [Abstract][Full Text] [Related]
11. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
[TBL] [Abstract][Full Text] [Related]
12. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
13. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
14. Haploidentical stem cell transplantation for acute leukemia.
Aversa F; Terenzi A; Felicini R; Carotti A; Falcinelli F; Tabilio A; Velardi A; Martelli MF
Int J Hematol; 2002 Aug; 76 Suppl 1():165-8. PubMed ID: 12430847
[TBL] [Abstract][Full Text] [Related]
15. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation.
Koehl U; Sörensen J; Esser R; Zimmermann S; Grüttner HP; Tonn T; Seidl C; Seifried E; Klingebiel T; Schwabe D
Blood Cells Mol Dis; 2004; 33(3):261-6. PubMed ID: 15528141
[TBL] [Abstract][Full Text] [Related]
16. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
[No Abstract] [Full Text] [Related]
17. Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
Meazza R; Ruggeri L; Guolo F; Minetto P; Canevali P; Loiacono F; Ciardelli S; Bo A; Luchetti S; Serio A; Zannoni L; Retière C; Colomar-Carando N; Parisi S; Curti A; Lemoli RM; Pende D
Front Immunol; 2023; 14():1111419. PubMed ID: 36865545
[TBL] [Abstract][Full Text] [Related]
18. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
Cooley S; He F; Bachanova V; Vercellotti GM; DeFor TE; Curtsinger JM; Robertson P; Grzywacz B; Conlon KC; Waldmann TA; McKenna DH; Blazar BR; Weisdorf DJ; Miller JS
Blood Adv; 2019 Jul; 3(13):1970-1980. PubMed ID: 31266741
[TBL] [Abstract][Full Text] [Related]
19. Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions.
Jaiswal SR; Zaman S; Chakrabarti A; Sen S; Mukherjee S; Bhargava S; Ray K; O'Donnell PV; Chakrabarti S
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1867-1873. PubMed ID: 27470289
[TBL] [Abstract][Full Text] [Related]
20. Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Kang YL; Lee JH; Lee JH; Kim DY; Lee JL; Park HS; Choi EJ; Lee YS; Kang YA; Jeon M; Seol M; Baek S; Yun SC; Kim HJ; Lee KH
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2065-2076. PubMed ID: 27530969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
